Navigation Links
Ambit Biosciences Announces Third Quarter 2013 Operating Results
Date:11/7/2013

November 14, 2013.  Interested parties can access the replay by dialing 888-843-7419 or 630-652-3042 internationally and entering the conference number 35977176.

The conference call webcast is accessible through the "Investors & Media" section of the Ambit website at http://www.ambitbio.com.  An online replay will be available following the initial broadcast until Saturday, December 7, 2013.  Please visit Ambit's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.

About Ambit Biosciences
Ambit is a biopharmaceutical company focused on the discovery, development and commercialization of drugs to treat unmet medical needs in oncology, autoimmune and inflammatory diseases by inhibiting kinases that are important drivers for those diseases. Ambit's lead drug candidate, quizartinib (AC220), is a once-daily, orally-administered potent and selective, inhibitor of FMS-like tyrosine kinase-3 (FLT3) and is currently under clinical development in patients with relapsed/refractory acute myeloid leukemia (AML) and in newly diagnosed AML patients in combination with chemotherapy as well as maintenance following a hematopoietic stem cell transplantation (HSCT). In addition to quizartinib, Ambit's clinical pipeline includes AC410, an oral JAK2 inhibitor, and CEP-32496, a BRAF inhibitor licensed to Teva Pharmaceutical Industries Ltd. Ambit's preclinical portfolio includes a proprietary CSF1R inhibitor program.

Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements associated with Ambit's expectations regarding future development and therapeutic potential of quizartinib and Ambit's other drug candidates, progress and timing o
'/>"/>

SOURCE Ambit Biosciences
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Ambit Announces Participation At 12th Annual BIO Investor Forum
2. Ambit Announces Participation At The BioCentury NewsMakers in the Biotech Industry Conference
3. Ambit Announces Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the Annual Meeting of the American Society of Clinical Oncology
4. Ambit Biosciences Files Registration Statement for Proposed Initial Public Offering
5. APAC Stem Cell Research & Therapy Market a “Growth Engine” for Region’s Scientific Ambitions Says A New Market Research Report at ReportsnReports.com
6. Astellas and Ambit Announce Data Presentations Highlighting Quizartinib at the American Society of Hematology 54th Annual Meeting
7. Ambit Biosciences to Present at Two Upcoming Investor Conferences
8. Ambit and Astellas Announce Results From Multiple Quizartinib Presentations at the 53rd Annual Meeting of the American Hematology Society
9. Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer
10. Pressure BioSciences, Inc. Reports Third Quarter 2013 Financial Results and Provides Business Update
11. Juneau Biosciences Names Dr. Dinesh Patel to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... CA (PRWEB) December 18, 2014 With ... limited time special on Sartorius Biohit products . ... on mLINE pipettes, Picus Electronic Pipette Trade-in Program, and ... Health and Safety officers around the world. They are ... pipetting. Other features include:, ,     Full volume ...
(Date:12/19/2014)... Dec. 18, 2014 Egenix, Inc. is pleased to ... Chairman of the Board, to succeed Donald Fresne ; ... will continue as a member of the Board.  In recognition ... to the company over almost twenty years, the Board designated ... of Directors has established a Search Committee to find a ...
(Date:12/19/2014)... YORK , Dec. 18, 2014 Relmada ... therapies for the treatment of chronic pain, announced the ... today. "This was a transformational year in ... promising future for our company," said Sergio Traversa ... year, we have executed on key financial, human resource ...
(Date:12/17/2014)... 2014 Based on the revenues ... imaging market is dominated by four major players ... market. These players include GE Healthcare (U.K.), Siemens ... , Full Report Copy at http://www.marketsandmarkets.com/Market-Reports/surgical-imaging-market-210534462.html ... can be attributed to its strong product portfolio, ...
Breaking Biology Technology:Major Pipette Distributor Pipette.com Announces Sartorius Year End Specials 2Relmada Therapeutics Announces Results of Annual Shareholders Meeting 2Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 2Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 3Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 4
... Inc. (Nasdaq: IDEV ) announced today the ... entitled "Once Daily Dosage Forms,of Trospium," which is ... Supernus Pharmaceuticals, Inc., The ,978 patent covers ... of trospium chloride which is indicated for the,treatment ...
... BRUNSWICK, N.J., Aug. 13 At the upcoming ... R&D Team,Leader, will present "Silicone Elastomer Gels: New ... place in Philadelphia, September 16-17., According to ... molecular,structures that provide differentiated performance features for wound ...
... - Test Cleared to Screen Donated Blood for Hepatitis ... C, on Fully and Semi-Automated Instrument Systems -, ... ) announced today that the US Food and Drug ... the,PROCLEIX(R) ULTRIO(R) assay to screen donated blood for the ...
Cached Biology Technology:Indevus Pharmaceuticals Announces Issuance of U.S. Patent for SANCTURA XR(TM) 2Indevus Pharmaceuticals Announces Issuance of U.S. Patent for SANCTURA XR(TM) 3Bluestar Silicones Presents Adhesive Gels for Wound Care at Medical Grade Polymers Conference 2FDA Grants Full Approval of PROCLEIX(R) ULTRIO(R) Blood Screening Assay 2FDA Grants Full Approval of PROCLEIX(R) ULTRIO(R) Blood Screening Assay 3FDA Grants Full Approval of PROCLEIX(R) ULTRIO(R) Blood Screening Assay 4
(Date:12/10/2014)... , Dec. 08, 2014 Research and Markets ... addition of the "Biometrics Market in Japan ... http://photos.prnewswire.com/prnh/20130307/600769 The ... such as rural banking and upgradation of the ... witnessed in the market. Besides the aforementioned projects, ...
(Date:12/5/2014)... Dec. 4, 2014 Increased emphasis on ... in new testing and inspection technologies. The convergence ... to a range of innovative test solutions. This ... Generation Y, which is generally more inclined towards ... product development strategies of test equipment vendors will ...
(Date:12/4/2014)... , Dec. 3, 2014  Crossmatch™, a leading ... that its DigitalPersona ® Pro Enterprise software ... been deployed throughout First Bank branch locations in ... South Carolina and Virginia. First Bank, a ... Southern Pines, North Carolina , selected the ...
Breaking Biology News(10 mins):Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3
... NSW Department of Primary Industries (DPI) fisheries scientists are ... fish caught and then released by anglers. , Some ... for released line-caught snapper, silver trevally, mulloway, sand whiting, ... costing more than $1.5 million and funded by NSW ...
... a mere 7 percent of its historic range, and the ... 41 percent over the past decade, according to an article ... in folk medicines made from tiger parts and tiger skins, ... the chief reason for the losses. The assessment, by Eric ...
... may seem unappealing to some, it has distinct nutritional ... behind the unusual hue. The finding may lead to ... and wheat. , The genetic mutation recently isolated ... and described in the December issue of The Plant ...
Cached Biology News:Releasing fish for the future 2Threats to wild tigers growing 2Discovery in orange cauliflower may lead to more nutritious crops 2
Vitronectin Immunogen: Purified, full length, native human protein. Storage: -20 C, Avoid Freeze/Thaw Cycles...
...
... Fully adjustable mixing angle, Variable speed, Digital ... a number of different sized tubes, Spillage ... cultures, keeping biological samples in suspension and ... be used in incubators up to 60C ...
... 2 real-time PCR detection system uses a ... (470-505 nm) and two photomultiplier tubes for ... Opticon 2 system is built on an ... thermal gradient feature. This item includes the ...
Biology Products: